News
ADCT
3.860
+1.31%
0.050
Weekly Report: what happened at ADCT last week (0406-0410)?
Weekly Report · 1d ago
Analysts’ Top Healthcare Picks: ADC Therapeutics (ADCT), Mirum Pharmaceuticals (MIRM)
TipRanks · 6d ago
Weekly Report: what happened at ADCT last week (0330-0403)?
Weekly Report · 04/06 10:03
ADC Therapeutics Earnings Call: Trials, Cash And Risks
TipRanks · 04/04 00:07
ADC Therapeutics Announces New Employee Inducement Grant
PR Newswire · 04/01 20:05
Weekly Report: what happened at ADCT last week (0323-0327)?
Weekly Report · 03/30 10:04
ADC Therapeutics Price Target Raised to $8.00/Share From $7.00 by HC Wainwright & Co.
Dow Jones · 03/23 11:02
ADC Therapeutics: Strengthening Fundamentals, ZYNLONTA Pipeline Momentum, and Increased $8 Target Support Buy Rating
TipRanks · 03/23 10:16
ADC Therapeutics price target raised to $8 from $7 at H.C. Wainwright
TipRanks · 03/23 10:10
Weekly Report: what happened at ADCT last week (0316-0320)?
Weekly Report · 03/23 10:00
ADC Therapeutics (ADCT) Gets a Buy from Guggenheim
TipRanks · 03/18 11:36
Weekly Report: what happened at ADCT last week (0309-0313)?
Weekly Report · 03/16 10:00
RBC Capital Sticks to Their Buy Rating for ADC Therapeutics (ADCT)
TipRanks · 03/12 01:45
Guggenheim Sticks to Their Buy Rating for ADC Therapeutics (ADCT)
TipRanks · 03/11 11:06
ADC Therapeutics (ADCT) Loss Narrowing To US$0.04 EPS Challenges Bearish Profitability Narrative
Simply Wall St · 03/10 22:20
ADC Therapeutics files to sell 9.83M common shares for holders
TipRanks · 03/10 21:15
ADC Therapeutics Narrows Losses, Supported By Higher Product Revenue And Ongoing Restructuring
NASDAQ · 03/10 14:17
ADC Therapeutics outlines $600M–$1B peak revenue target for ZYNLONTA as LOTIS-5 and LOTIS-7 advance
Seeking Alpha · 03/10 14:00
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/10 12:35
ADC Therapeutics Posts Narrower Loss In Q4
NASDAQ · 03/10 12:24
More
Webull provides a variety of real-time ADCT stock news. You can receive the latest news about Adc Therapeutics Sa through multiple platforms. This information may help you make smarter investment decisions.
About ADCT
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.